SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop new therapeutic approach for geographic atrophy – advanced form of dry AMD
29-Apr-2024 -
SeaBeLife, a biotechnology company developing drug candidates intended to block cellular necrosis, announces the award of more than €1.5M ($1.6M) in financing for its SeaBeEYE project at the i-Nov 2024 innovation competition. Funded by the French government’s France 2030 investment plan and ...
age-related macular degeneration
atrophy
financing
+1